Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2

Junu A. George and Seong Kug Eo*
College of Veterinary Medicine and Bio-Safety Research Institute, Chonbuk National University, Jeonju 561-756, Korea

Background: Dengue virus, which belongs to the Flavivirus genus of the Flaviviridae family, causes fatal dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) with infection risk of 2.5 billion people worldwide. However, approved vaccines are still not available. Here, we explored the immune responses induced by alternating prime-boost vaccination using DNA vaccine, adenovirus, and vaccinia virus expressing E protein of dengue virus type 2 (DenV2).

Methods: Following immunization with DNA vaccine (pDE), adenovirus (rAd-E), and/or vaccinia virus (VV-E) expressing E protein, E protein-specific IgG and its isotypes were determined by conventional ELISA. Intracellular CD154 and cytokine staining was used for enumerating CD4+ T cells specific for E protein. E protein-specific CD8+ T cell responses were evaluated by in vivo CTL killing activity and intracellular IFN-γ staining.

Results: Among three constructs, VV-E induced the most potent IgG responses, Th1-type cytokine production by stimulated CD4+ T cells for E protein, and the CD8+ T cell response. Furthermore, when the three constructs were used for alternating prime-boost vaccination, the results revealed a different pattern of CD4+ and CD8+ T cell responses. i) Priming with VV-E induced higher E-specific IgG level but it was decreased rapidly. ii) Strong CD8+ T cell responses specific for E protein were induced when VV-E was used for the priming step, and such CD8+ T cell responses were significantly boosted with pDE. iii) Priming with rAd-E induced stronger CD4+ T cell responses which subsequently boosted with pDE to a greater extent than VV-E and rAd-E.

Conclusion: These results indicate that priming with live viral vector vaccines could induce different patterns of E protein-specific CD4+ and CD8+ T cell responses which were significantly enhanced by booster vaccination with the DNA vaccine. Therefore, our observation will provide valuable information for the establishment of optimal prime-boost vaccination against DenV.

INTRODUCTION

Dengue virus (DenV) has four serotypes (DenV1, DenV2, DenV3, and DenV4), and belongs to the Flavivirus genus of the Flaviviridae family transmitted to humans by the mosquito Aedes aegypti (1-3). DenV poses a significant public health threat to 2.5 billion people at the risk of infection (1-3). Around 100 million cases of DenV infections occur annually, producing symptoms ranging from mild fever to severe hemorrhagic, potentially fatal fever (1-3). Dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which reportedly affect about 500,000 people per year, are potentially fatal diseases (1-3). These diseases are spreading from tropical to subtropical areas of the world by global warming, increasing travel activity, and uncontrolled urbanization (1-3). Despite global morbidity and mortality, the pathogenesis of diseases caused by DenV infection is poorly understood. Even though several factors such as viral virulence, age and genetic predisposition of the patient are implicated, the most important factor is considered to be sequential infection by different serotypes in an endemic area (4,5). While approved vaccines remain unavailable, several approaches to develop a dengue vaccine have been evaluated. These include the tra-
ditional live attenuated vaccines (6-9), recombinant subunit vaccines produced using several different host systems (10-13), chimeric virus such as yellow fever vaccine vector YF17D-based ChimeriVax (14,15) and RepliVax (16), and DNA vaccine (17,18).

All four dengue serotypes have co-circulated in most endemic countries at various times, thereby causing concurrent and/or sequential infection by multiple serotypes (19). Furthermore, there is the potential for antibody-dependent enhancement (ADE) associated with non-neutralizing cross-reactive antibodies arising from immunization with monovalent dengue virus vaccines (19). Therefore, a dengue virus vaccine should elicit protective immunity simultaneously to all four serotypes. The current approach to making a tetravalent dengue vaccine is to create monovalent vaccine candidates, and then mix these to obtain a tetravalent formulation (20-22). The application of this approach to live, replicating virus vaccine has revealed the potential for viral interference in some instances (22,23). Considering viral interference in vaccination with live viral vector vaccine, multiple prime-boost vaccinations with alternating vaccine vehicles using DNA vaccine expressing the same antigen may become an effective strategy for eliciting robust immune responses to the target antigen (24). Notably, the prime-boost protocol, in which antigen-encoding DNA vaccine is administered first, followed by a boost with live viral vector expressing the same antigen, has elicited effective protective immunity in both mouse and primate models of several infectious diseases (25,26). However, some experiments showed that priming with live viral vector vaccine and boosting with DNA vaccine induces superior immune responses against encoded antigens (27,28), which suggest that optimal prime-boost protocol may be dependent on several factors such as encoded antigens, animal species, and properties of vaccine vectors.

Various viral vectors expressing foreign antigen, such as vaccinia virus, adenovirus or Fowlpox have been used for prime-boost vaccination, DNA- and vaccinia-based vaccines for a pre-erythrocytic malaria antigen that were delivered in a prime-boost protocol induced 5- to 10-fold greater T-cell responses than each vaccine alone (29). In addition, gene-based vectors, such as replication-incompetent adenovirus, have proven particularly effective in eliciting enhanced cellular and humoral immunities compared to either agent alone (30,31). Replication-incompetent adenovirus has the ability to efficiently deliver antigens and express them at high levels in a variety of cells, making them ideal vaccine carriers (32,33). In contrast, vaccinia virus-vectored recombinants show unrestricted replication in immune-compromised individuals (34).

Here, we explored the immune responses induced by alternating prime-boost vaccination using these different viral vector vaccines expressing E protein of DenV2, which is a major immunogen involved in conferring protective immunity against dengue infection. We found that vaccinia virus expressing E protein produced better responses compared to adenovirus at equivalent antigen doses, and these viral vectors elicited different patterns of CD4+ and CD8+ T cell responses against E protein when used for alternating prime-boost vaccination. Therefore, humoral and cellular immune responses induced by alternating prime-boost vaccination using live viral vector vaccine, vaccinia and adenovirus, and DNA vaccine are discussed.

**MATERIALS AND METHODS**

**Animals and ethics statement**

Female BALB/c (H-2d) mice, 5 to 6 weeks of age, were purchased from Samtako (Osan, Korea). The mice were maintained in the animal facility at Chonbuk National University under standard conditions. All experimental procedures and animal management procedures were undertaken in accordance with the requirement of the Animal Care and Ethics Committees of Chonbuk National University. The animal facility at Chonbuk National University is fully accredited by the National Association of Laboratory Animal Care.

**Plasmid DNA preparation**

Plasmid DNA encoding E protein of dengue virus type 2 (DenV2) under the control of the cytomegalovirus (CMV) promoter (pDE) was constructed by inserting cDNA of the E protein gene into pCI-neo vector (Promega, Madison, WI). For immunization, plasmid DNA was purified by polyethylene glycol (PEG) precipitation as described previously (35). Briefly, cellular proteins were precipitated with one volume of 7.5 M ammonium acetate followed by isopropanol precipitation of the supernatant. After PEG precipitation, the plasmid was extracted three times with phenol-chloroform and precipitated with pure ethanol. The DNA quality was checked by electrophoresis on a 1% agarose gel. The plasmid DNA concentration was measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Pittsburgh, PA). The amount of endotoxin was determined by the Limulus
amebocyte lysate (LAL) test (<0.05 EU/μg). The in vivo effect of endotoxin and CpG was addressed by parallel administration of the control vector, pCl-neo.

**Construction of recombinant adenovirus expressing E protein**

The E1- and E3-deleted expression vector into which E protein of DenV2 is cloned was used to construct replication-incompetent adenovirus expressing E protein of DenV2 (36). E protein of DenV2 was expressed in the replication-incompetent adenovirus by cloning E protein gene under the control of the human CMV promoter. We initially constructed recombinant entry vector pENTR11 (Invitrogen, Carlsbad, CA) containing E protein gene by RT-PCR amplification and subcloning. Using LR Clonase (Invitrogen) for catalysis, the recombinant adenoviral plasmid DNA containing E protein gene were mixed with adenoviral destination vector, pAd/CMV/V5-DEST (Invitrogen), to generate recombinant adenoviral plasmid containing E protein gene. After transforming the recombinant adenoviral plasmid DNA into competent E. coli, we extracted and purified DNA from selected putative positive clones identified by PCR amplification and gel electrophoresis. Those putative clones were also cultured on LB plates containing 30 μg/ml chloramphenicol, since true expression clones would be ampicillin-resistant and chloramphenicol-sensitive. Following digestion of the recombinant adenoviral plasmid DNA containing E protein gene with the restriction enzyme PacI, human embryonic kidney 293A cells were transfected to generate replication-incompetent adenovirus. Culture medium was replaced with fresh complete culture medium every 2–3 days until visible regions of the cytopathic effect (CPE) were observed. When approximately 50–70% CPE was observed, adenovirus-containing cells and media were harvested. The expression of E protein was identified with RT-PCR after NIH3T3 cells were infected with rAd-E. The replication-incompetent adenovirus expressing E protein of DenV2 (rAd-E) were purified with the Adeno-X mini purification kit (Clontech, Mountain View, CA), titrated by plaque assay, and stored at −80°C until use.

**Construction of vaccinia virus expressing E protein**

Recombinant vaccinia virus expressing E protein of DenV2 (VV-E) was constructed using the shuttle vector, pSG11 (provided by Dr. B. Moss, NIH, Bethesda, MD) (37). Plasmid pSG11 encoding E protein gene was subcloned from pGEMT/E vector by restricting the plasmid using BglII and ScaI endonucleases. Human thymidine kinase-deficient 143B cell (HuTK- cells) were grown to 80% confluency in Eagle’s Minimum Essential Medium (MEM) containing 5% FBS. They were infected with vaccinia virus strain WR at a multiplicity of infection (MOI) of 0.05 followed by transfection with pSG11 encoding E protein gene using Lipofectamine (Gibco-BRL, Grand Island, NY). After CPE had developed (usually in 48–72 h), the cells were ruptured and the cell lysates containing the putative recombinant virions were employed to plaque isolation in the presence of bromodeoxyuridine (BrdU; 25 μg/ml) and Bluo-gal (0.6 mg/ml; Gibco-BRL). Blue plaques, produced by replicating recombinant virion expressing the lacZ gene, were collected and used to enhance the virus content of the plaques by inoculating a confluent layer of HuTK- cells. Recombinant vaccinia virus expressing E protein of DenV2 were harvested, plaques purified and enhanced by infecting larger volumes of two or more cell monolayers. The expression of E protein by recombinant vaccinia virus was confirmed by immunoblot. The titers of recombinant vaccinia virus were determined by plaque assay and stored at −80°C until needed.

**Protocol for vaccination and sample collection**

Groups of mice (5- to 6-weeks old female) were immunized with either 100 μg of pDE or 10^5 PFU of rAd-E and VV-E via the intramuscular (i.m.) route. In prime-boost experiments, primarily immunized mice were boosted 7 days later with alternative vaccine vehicle via the same route. The i.m. immunization was performed by injecting the indicated immunogen into the anterior tibialis muscle. Control mice were given the empty vector (pCl-neo), replication-incompetent adenovirus expressing the LacZ gene (rAd-LacZ), and vaccinia virus expressing chicken ovalbumin (VV-OVA). Serum samples were collected by retro-orbital bleeding and stored at −80°C until needed.

**ELISA for E specific antibody, IgG, IgG1, and IgG2a**

A standard enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of E-specific antibodies in the serum samples. Briefly, ELISA plates were coated overnight at 4°C with E protein (100 ng/well) in the sample wells and goat anti-mouse IgG/IgG1/IgG2a (Southern Biotechnology Associate Inc., Birmingham, AL) in standard wells. E protein of DenV2 was purified from recombinant E, coli by the Ni-NTA His-Tag column (Peptron Co. Ltd, Daejeon, Korea). The plates were washed three times with PBS-Tween 20.
were incubated at 37°C for an additional 2 h. The plates were washed and incubated with peroxidase-conjugated streptavidin biotinylated IL-2, IL-4, and IFN-γ antibodies (eBioscience; clone no. JES6-5H4, BVD6-24G2, and R4-6A2, respectively) were added, after which the plates were washed and incubated with peroxidase-conjugated streptavidin. The concentrations of E-specific antibodies was determined using an automated ELISA reader and the SOFTmax Pro4.3 program (Spectra MAX40; Molecular Device, Sunnyvale, CA).

**Cytokine ELISA following in vitro stimulation of CD4+ T cells**

To examine cytokine production from stimulated CD4+ T cells, splenocytes prepared from immunized mice were used as responder cells. The syngeneic antigen-presenting cell (APC) populations enriched by OptiPrep™ gradient (13.8% iodixanol; Axis-Shield, Oslo, Norway) (38) were pulsed with E protein (100 μg/ml) and subsequently used as stimulators. The responder and E protein-pulsed stimulator cells were combined at responder-to-stimulator ratios of 5:1, 2.5:1, and 1.25:1 in 200 μl of RPMI medium. The culture supernatants were harvested after 3 days of incubation. A similar number of responder cells were stimulated with 5 μg of concanavalin A for 48 h as a polyclonal positive stimulator.

ELISA was used to determine cytokine levels of IL-2, IL-4, and IFN-γ in the culture supernatants. Briefly, 100 ng per well of either IL-2, IL-4, or IFN-γ anti-mouse antibody (eBioscience, San Diego, CA; clone no. JES6-1A12, 11B11, and R4-6A2, respectively) was added to each ELISA plate. The plates were then incubated overnight at 4°C and then washed three times with PBS-Tween 20. Next, they were blocked with 3% non-fat dehydrated milk for 2 h at 37°C. The culture supernatant and recombinant IL-2, IL-4, and IFN-γ protein (Pharmingen, San Diego, CA) as standards were used. Each of these reagents was serially diluted two-fold, and then added to the corresponding plates. The plates were then incubated overnight at 4°C. Next, biotinylated IL-2, IL-4, and IFN-γ antibodies (eBioscience; clone no. JES6-5H4, BVD6-24G2, and XMG1.2, respectively) were added, after which the plates were incubated at 37°C for an additional 2 h. The plates were then washed and incubated with peroxidase-conjugated streptavidin (Pharmingen) for 1 h, after which the color was developed with the addition of a substrate (2,2-azinobis-3-ethylbenzothiazoline-6-sulfonic acid in a mixture of 25 ml of 0.1 M citric acid, 25 ml of 0.1 M sodium phosphate, and 10 μl of hydrogen peroxide). The concentration of cytokines was then determined using an automated ELISA reader and the SOFTmax Pro4.3 program to compare the samples to two concentrations of standard cytokine protein. Data were expressed by subtracting the produced cytokine levels of no E protein-treated cultures from cytokine produced from E protein-stimulated cultures.

**Intracellular CD154 staining for E-specific CD4+ T cells**

We used intracellular CD154 staining to identify E protein-specific CD4+ T cells, as previously described (39,40). Briefly, 10^6 freshly explanted splenocytes per well were stimulated with E protein (100 μg/ml) in U-bottom 96-well plates for 12 h, Brefeldin A (2 μg/ml) was added for the last 6 h culture period to facilitate intracellular CD154 accumulation. After 12 h-stimulation, cells were washed twice with PBS containing 1% BSA, 0.05% NaN₃, and 2 μg/ml brefeldin A. Cells were subsequently incubated with FITC-conjugated anti-CD4, PE-conjugated anti-CD154 for 30 min at room temperature. After several washes, the intracellular CD154 molecules were determined by flow cytometry.

**In vivo CTL killing activity**

An in vivo CTL assay was conducted as reported elsewhere (41). Splenocytes were collected from recipient mice 24 h after adoptive transfer of target cells that were previously pulsed with E_{331-339} (H-2Ld; SPCKIPFEI) epitope peptide (1 μg/ml) and labeled with CFSE (2.5 μM), and then analyzed by flow cytometry. To control for antigen specificity, unpulsed syngeneic splenocytes previously labeled with CFSE (0.25 μM) were injected intravenously (i.v.) along with target cells. Each population was distinguished by their respective fluorescence intensity. The percentage of killing of target cells in immunized mice was calculated using the following equation: ratio = (percentage of CFSE<sup>low</sup>/percentage of CFSE<sup>high</sup>). The percentage of specific lysis = (1 - [ratio of naive/ratio of immunized])/100.

**Intracellular IFN-γ staining for E<sub>331-339</sub>-specific CD8+ T cells**

Single-cell suspension (5 × 10⁶ cells/ml) of splenocytes isolated from immunized mice was incubated with E<sub>331-339</sub> (H-2Ld; SPCKIPFEI) epitope peptide (2 μg/ml) in RPMI media
supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C. After 6 h-incubation, the stimulated splenocytes were employed to stain surface CD8 followed by staining intracellular IFN-γ. The IFN-γ-producing CD8+ T cells was determined by flow cytometry.

Statistical analysis
Data are expressed as the average±standard deviation (SD) of the individual results. Where specified, the data were analyzed for statistical significance using an unpaired two-tailed Student t test. A value of p<0.05 was considered statistically significant.

RESULTS
Humoral immune responses induced by plasmid DNA and live viral vectors expressing E protein
To evaluate the immune responses induced by plasmid DNA (pDE), recombinant adenovirus (rAd-E) and vaccinia virus (VV-E) expressing E protein of DenV2, groups of mice were immunized with these constructs and the levels of E-specific IgG in sera were determined 10 days post-immunization. pDE was observed to induce lower levels of E-specific IgG when compared to live viral vectors (Fig. 1A). VV-E induced significantly higher levels of E-specific IgG than rAd-E at the equivalent amount of immunogens (10^6 PFU/mouse). When the distribution of E-specific IgG isotypes, IgG1 and IgG2a, was evaluated, VV-E showed significantly higher levels of E-specific IgG1 and IgG2a compared to pDE and rAd-E (Fig. 1B and C). However, three constructs expressing E protein of DenV2 showed comparable ratios of IgG2a to IgG1 each other (Fig. 1D). These results indicate that constructed pDE, rAd-E and VV-E could successfully induce humoral responses specific for E protein of DenV2.

CD4+ T cell responses induced by plasmid DNA and live viral vectors expressing E protein
After immunizing mice with pDE, rAd-E and VV-E, the cytokine production from CD4+ T cells in response to E protein stimulation was determined 14 days post-immunization, CD4+ T cells prepared from VV-E immunized mice produced higher amounts of IL-2 and IFN-γ in response to E protein stimulation, compared to those isolated from mice immunized by either pDE or rAd-E (Fig. 2A∼C). In contrast, immunization with rAd-E exhibited a significantly higher production of IL-4 compared to other forms of immunization (Fig. 2B). To understand immune responses induced by pDE, rAd-E or VV-E in detail, we determined the number of CD4+ T cells specific for E protein using intracellular CD154 staining (39,40). In
Immunity Induced by Alternating Prime-boost Vaccination against DenV2
Junu A. George and Seong Kug Eo

Figure 2. Evaluation of CD4+ T cell responses specific for E protein of DenV following immunization with plasmid DNA and live viral vectors.

Two weeks after immunization with plasmid DNA (pDE), recombinant adenovirus (rAd-E) and vaccinia virus (VV-E) expressing E protein of DenV, splenocytes prepared from immunized mice were stimulated with E protein-pulsed syngeneic APCs for 3 days. The levels of IL-2 (A), IL-4 (B), and IFN-γ (C) in culture supernatants were determined by ELISA. Plasmid DNA empty vector (pCIneo), recombinant adenovirus expressing LacZ (rAd-LacZ), and vaccinia virus expressing OVA (VV-OVA) were used as the negative control. (D) The percentage of CD4+ T cells responded by E protein stimulation was determined by intracellular CD154 staining assay. Data represent average and standard deviation derived 4 mice per group. *p <0.05; **p <0.01 compared between the indicated groups.

CD8+ T cell responses induced by plasmid DNA and live viral vectors expressing E protein

Consistent, VV-E immunization showed higher percentages of CD154+CD4+ T cells in response to E protein stimulation (Fig. 2D). Therefore, this result indicates that plasmid DNA and live viral vectors expressing E protein induced CD4+ T cell responses and VV-E immunization induced the most potent immune responses.

Humoral immune responses induced by alternating prime-boost immunization using plasmid DNA and live viral vectors expressing E protein

To compare E-specific immune responses induced by alternating prime-boost immunization with pDE, rAd-E, and VV-E, we first assessed the humoral responses following immunization with the indicated protocols (Fig. 4A). The primary immunization with vaccinia virus expressing E protein followed by boosting with adenovirus expressing E protein showed highest levels of E-specific IgG, but E-specific IgG lasted for 14 days post-boosting with higher levels in the group that received priming with rAd-E and boosting with VV-E. In general, it was observed that the levels of E-specific IgG in sera rapidly decreased when VV-E was used as immunogen of primary vaccination. Furthermore, priming with VV-E and boosting with rAd-E led to production of E-specific IgG1 isotype with higher levels than the other group, when the levels of E-specific IgG isotypes, IgG1 and IgG2a, were determined (Fig. 4B and C). Notably, if VV-E was used for primary vaccination, the levels of E-specific IgG1 isotype were maintained till 14 days post-boosting, but E-specific IgG2a levels decreased. Therefore, these results suggest that E-specific IgG and its isotypes, IgG1 and IgG2a, may be produced at various levels by alternating prime-boost immunization using DNA
Immunity Induced by Alternating Prime-boost Vaccination against DenV2
Juna A. George and Seong Kug Eo

Figure 3. CD8+ T cell responses specific for E protein of DenV following immunization with plasmid DNA and live viral vectors. (A) In vivo CTL killing activity. Groups of mice were immunized with plasmid DNA (pDE), recombinant adenovirus (rAd-E), and vaccinia virus (VV-E) expressing E protein, and used for in vivo CTL killing activity 14 days later. (B) IFN-γ-producing CD8+ T cells in response to epitope peptide stimulation. Splenocytes prepared from immunized mice were stimulated with E331-339 (SPCKIPFEI) epitope peptide for 8 h and used for intracellular cytokine staining. Plasmid DNA empty vector (pCIneo), recombinant adenovirus expressing LacZ (rAd-LacZ), and vaccinia virus expressing OVA (VV-OVA) were used as the negative control. Data represent average and standard deviation derived from 4 mice per group. *p<0.05; **p<0.01 compared between the indicated groups.

Figure 4. Serum IgG and its isotypes specific for E protein of DenV following alternating prime-boost immunization with plasmid DNA and live viral vectors. Groups of mice that received plasmid DNA (D), recombinant adenovirus (A), or vaccinia virus (V) expressing E protein of DenV were boosted with alternate vehicle 7 days post-immunization. The levels of E-specific IgG (A), and its isotypes, IgG1 (B) and IgG2a (C), were determined by conventional ELISA 7 and 14 days post-boosting. Data represent average and standard deviation derived from 5 mice per group.

CD4+ T cell responses induced by alternating prime-boost immunization using plasmid DNA and live viral vectors expressing E protein

When the production of Th1- and Th2-type cytokines by CD4+ T cells stimulated with E protein was analyzed, the results showed a different pattern from E-specific IgG (Fig. 5). The group of mice that received priming with rAd-E and boosting with pDE showed a higher production of IL-2 and IFN-γ from stimulated CD4+ T cells (Fig. 5A and C). However, priming with VV-E and boosting with rAd-E that showed the highest level of E-specific IgG induced lower production of IL-2 and IFN-γ from stimulated CD4+ T cells. IL-4 production by CD4+ T cells showed no pattern correlated with the protocols of alternating prime-boost vaccination using DNA vaccine and live viral vectors (Fig. 5B). Furthermore, when E-specific CD4+ T cells producing IFN-γ were enum-
Immunity Induced by Alternating Prime-boost Vaccination against DenV2
Junu A. George and Seong Kug Eo

Figure 5. Th1- and Th2-type cytokine production from CD4+ T cells by stimulation with E protein of DenV following alternating prime-boost immunization with plasmid DNA and live viral vectors. Groups of mice that received plasmid DNA (D), recombinant adenovirus (A), or vaccinia virus (V) expressing E protein of DenV were boosted with alternate vehicle 7 days post-immunization. Two weeks after boosting, splenocytes prepared from were stimulated with E protein-pulsed syngeneic APCs for 3 days. The levels of IL-2 (A), IL-4 (B), and IFN-γ (C) in culture supernatants were determined by ELISA. Data represent average and standard deviation derived from 5 mice per group. *p<0.05; **p<0.01; ***p<0.001 compared between the indicated groups.

Figure 6. Enumeration of IFN-γ-producing CD4+ T cells by E protein stimulation. Two weeks after boosting, splenocytes prepared from immunized mice were stimulated with E protein-pulsed syngeneic APCs for 12 h, and the percentages (A) and number (B) of IFN-γ-producing CD4+ T cells were determined by intracellular staining of IFN-γ and CD154. Data represent average and standard deviation derived from 4 mice per group. **p<0.01; ***p<0.001 compared between the indicated groups.

erated by intracellular CD154 and IFN-γ staining (39,40), the results revealed that priming with rAd and boosting with pDE induced the highest number of IFN-γ-producing E-specific CD4+ T cells than other immunization (Fig. 6A). Similarly, groups of mice that received priming with rAd-E and boosting with VV-E exhibited a higher number of IFN-γ-producing E-specific CD4+ T cells in spleen (Fig. 6B). Of particular interest, priming with pDE showed inhibited CD4+ T cell responses after boosting with either rAd-E or VV-E. Taken together, these results indicate that CD4+ T cell responses achieved by priming with adenovirus expressing E protein and boosting with DNA vaccine were superior to other immunization protocols, and primary responses induced by DNA vaccine may interfere with CD4+ T cell responses of liver viral vector as booster.

CD8+ T cell responses induced by alternating prime-boost immunization using plasmid DNA and live viral vectors expressing E protein

When CD8+ T cell responses specific for E protein of DenV2 were determined by in vivo CTL killing activity, the results revealed that priming with VV-E and boosting with pDE showed the most potent in vivo CTL killing activity (Fig. 7A).
Immunity Induced by Alternating Prime-boost Vaccination against DenV2
Jun A. George and Seong Kug Eo

Figure 7. CD8+ T cell responses specific for E protein of DenV following alternating prime-boost immunization with plasmid DNA and live viral vectors. (A) In vivo CTL killing activity. Groups of mice that received plasmid DNA (D), recombinant adenovirus (A), or vaccinia virus (V) expressing E protein of DenV were boosted with an alternate vehicle 7 days post-immunization. In vivo CTL killing activity was determined 14 days post-boosting. (B and C) IFN-γ-producing CD8+ T cells in response to epitope peptide stimulation. Splenocytes prepared from mice immunized with alternating prime-boost vaccine vehicles were stimulated with E331-339 (SPCKIPFEI) epitope peptide for 8 h and used for intracellular cytokine staining. Data represent average and standard deviation derived from 4 mice per group. **p < 0.01; ***p < 0.001 compared between the indicated groups.

This exceeded the results achieved by priming and boosting with the same vaccine VV-E, and was superior to responses induced by priming with rAd-E and boosting with pDE. Groups of mice that received pDE as primary immunogen showed lower in vivo CTL killing activity than with other methods. Consistently, priming with VV-E and boosting with pDE showed a higher number of IFN-γ-producing CD8+ T cells in response to stimulation with E331-339 (SPCKIPFEI) epitope peptide (Fig 7B and C). Also, the number of IFN-γ-producing CD8+ T cells induced by primary immunization with pDE was not increased by boosting with live viral vectors including rAd-E and VV-E. These results indicate that boosting with DNA vaccine expressing E protein of DenV2 following primary immunization with live viral vectors elicits strong CD8+ T cell responses.

DISCUSSION

We demonstrate that DNA vaccine, adenovirus, and vaccinia virus expressing E protein of DenV2 induced differential immune responses. Among three constructs, VV-E induced the most potent IgG responses, Th1-type cytokine production by stimulated CD4+ T cells, and CD8+ T cell response. rAd-E showed higher production of Th2-type cytokine IL-4 compared to other constructs, DNA vaccine and vaccinia virus. Furthermore, when such constructs were used for alternating prime-boost vaccination, the results revealed a different pattern of immune responses, depending on the constructed vaccine used for the priming step. Notably, priming with VV-E induced higher E-specific IgG levels which rapidly decreased compared to the group that received rAd-E as a priming vaccine. Also, strong CD8+ T cell responses specific for E protein were induced when VV-E was used for priming the vaccine vehicle, and such CD8+ T cell responses were significantly boosted with pDE vaccination, compared to booster vaccination with either rAd-E or VV-E. In contrast, priming with rAd-E induced stronger CD4+ T cell responses which subsequently boosted DNA vaccination more than others, as determined by intracellular CD154 and IFN-γ staining. Therefore, these results indicate that priming with live viral vector vaccine could lead to a different pattern of E protein-specific immune responses that were significantly more enhanced by booster vaccination with DNA vaccine, compared to live viral vector vaccine.

Vaccination protocols commonly require multiple immunizations to achieve robust, protective, and sustained immune responses. In particular, heterologous prime-boost vaccination with DNA vaccine and live viral vector vaccine has emerged as an effective strategy for eliciting a robust response to target antigen (25,26). In such vaccination strategies, the most effective approach has proven to be priming with DNA vaccine and boosting with recombinant viral vector expressing the same antigen (25,26). This approach has been used extensively in the development of vaccines against a
number of pathogens including human immunodeficiency virus (HIV) (42,43), herpesvirus (44), hepatitis C virus (HCV) (30), Ebola virus (45), and highly pathogenic avian influenza virus (HPAI) H5N1 (46,47). However, this dogma has sometimes been challenged by different results which show that priming with either live viral vector or live attenuated vaccine and boosting with DNA vaccine showed stronger responses than priming with DNA vaccine and boosting with live viral vector (27,28). In addition, priming with live viral vector vaccine and boosting with DNA vaccine induced the most potent immune responses at both systemic and mucosal sites if prime-boost vaccination is applied to mucosal route (48). Our results support the later notion at least in prime-boost vaccination against E protein of dengue virus type 2. Of particular interest, a different magnitude of CD4+ and CD8+ T cell responses were induced if either rAd-E or VV-E is used as priming vaccine vector. Minutely, priming with rAd-E induced higher number of CD4+ T cells specific for E protein following boosting with pDE, whereas stronger CD8+ T cell responses were induced by priming with VV-E followed by boosting with pDE. The reason that priming with viral vector vaccine and boosting with pDE showed effective immune responses may be explained by escape of DNA vaccine to interference conferred by pre-existing immunity (22,23,49). Conceivably, it is possible that pre-existing immunity induced by priming with pDE or live viral vector vaccine (rAd-E and VV-E) could inhibit immune responses provided by boosting with live viral vaccine expressing the same antigen, E protein. Indeed, the group that received pDE at both priming and boosting showed stronger CD4+ responses than the group that received priming with pDE and boosting with either rAd-E or VV-E (Fig. 6). However, how priming with either rAd-E or VV-E induced different patterns of CD4+ and CD8+ T cell responses following boosting with pDE remains to be explained.

Alternating prime-boost immunization is known to confer synergistically stronger responses to antigens and greater protection than immunization with either vaccine alone (25,26). However, the immunological basis for this outcome remains to be resolved. It is likely that the success of this approach may depend on several factors. In some instances, immune responses to repeated administration of the vector used for the primary immunization can neutralize the immunity induced by a booster, thereby inhibiting the effective immune responses that follow boosting. Also, the prime-boost vaccination may enable encoded antigen to be presented through alternative modes, depending on the diversity of antigen delivery. In particular, boosting with live viral vector may selectively expand the small population of antigen-specific CD4/CD8 T cells by inducing type I IFN production, leading to IL-15 production, which has been known to maintain CD8+ T cell proliferation and survival (50,51). Moreover, adenovirus appears to infect early dendritic cells (DCs), which may differentiate to mature DCs that present antigens more effectively (30,31). Adenovirus also synthesizes larger quantities of proteins that are taken up by endocytosis. Similarly, vaccinia virus can replicate in several types of epithelial cells as well as antigen-presenting cells to provide antigen for cognate lymphocytes. In the present study, we used replication-incompetent adenovirus that can provide antigen protein from infected cells, whereas vaccinia virus can replicate in some cells of immunocompromised hosts. Thus, it is possible that vaccinia virus could induce stronger responses compared to the adenovirus at equivalent antigen doses (Fig. 1). Also, the divergent cell targeting and antigen presentation of adenovirus and vaccinia virus complement each other in prime-boost vaccination, allowing a greater outcome of immune responses than with either vaccine vehicle alone.

Optimal vaccination to provide protective immunity against dengue virus is still challenging. One of the major issues to develop vaccines against dengue infection is how to effectively provide protective immunity against all four serotypes of the dengue virus. We hope that the alternating prime-boost vaccination using DNA vaccine, adenovirus, and vaccinia virus expressing E protein can be used as an effective prophylactic strategy to control fatal DHF and DSS caused by dengue infection. To achieve the practical development of vaccination strategies against dengue virus, the prime-boost vaccination using DNA vaccine and/or live viral vector vaccine expressing tetravalent antigen is recommended. Therefore, our observation will provide valuable information for the establishment of optimal prime-boost vaccination against dengue virus.

ACKNOWLEDGEMENTS

This study was supported by the Mid-career Research Program (2010-0000134, 2010-0029108) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology. The authors thank Dr. B. Moss (NIH, USA) for supplying pSC11 shuttle vector.
CONFLICTS OF INTEREST

The authors have declared that there is no conflict of interest.

REFERENCES

1. Swaminathan S, Khanna N: Dengue: recent advances in biology and current status of translational research, Curr Mol Med 9:152-173, 2009.
2. Guha-Sapir D, Schimper B: Dengue fever: new paradigms for a changing epidemiology, Emerg Themes Epidemiol 2:1, 2005.
3. Halstead SB: Dengue, Lancet 370;1644-1652, 2007.
4. Rothman AL: Dengue: defining protective versus pathologic immunity, J Clin Invest 113;946-951, 2004.
5. Stephenson JR: Understanding dengue pathogenesis: implications for vaccine design, Bull World Health Organ 83;308-815, 2005.
6. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gibson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers, Vaccine 19;3179-3188, 2001.
7. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thanas N, Vaughn DW, Innis BL, Sun W: Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine, Am J Trop Med Hyg 69(6 Suppl);4860, 2003.
8. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang NJ, Saluzzo JF: Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults, Vaccine 24;1238-1241, 2006.
9. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R: Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults, Hum Vaccin 5;33-40, 2009.
10. Kelly FP, Greene JJ, King AD, Innis BL: Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice, Vaccine 18;2549-2559, 2000.
11. Muné M, Rodríguez R, Ramírez R, Soto Y, Sierra B, Rodríguez Roche R, Marquez G, Garcia J, Guillén G, Guzmán MG: Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice, Arch Virol 148;2267-2273, 2003.
12. Hermida L, Rodríguez R, Lazo L, Bernado L, Silva R, Zulueta A, López C, Martín J, Valdés I, del Rosario D, Guillén G, Guzmán MG: A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal PspV protein carrier, induces a functional immune response in mice, Biotechnol Appl Biochem 39;107-114, 2004.
13. Hermida L, Bernardo L, Martín J, Alvarez M, Prado I, López C, Sierra Bde L, Martínez R, Rodríguez R, Zulueta A, Pérez AB, Lazo L, Rosario D, Guillén G, Guzmán MG: A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates, Vaccine 24;3165-3171, 2006.
14. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS: Genetically modified, live attenuated dengue virus type 3 vaccine candidates, Am J Trop Med Hyg 71:811-821, 2004.
15. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS: Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys, J Virol 79;5516-5528, 2005.
16. Suzuki R, Winkelmann ER, Mason PW: Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2, J Virol 85;1870-1880, 2009.
17. Azevedo AS, Yamamura AM, Freire MS, Trindade GF, Baldonado M, Galler R, Alves AM: DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III, PLoS One 6;250, 2011.
18. Konishi E, Miyagawa Y: Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model, Micobacter Infect 13;1091-1098, 2011.
19. Whitehorn J, Simmons CP: The pathogenesis of dengue, Vaccine, 29;7221-7228, 2011.
20. Halstead SB, Deen J: The future of dengue vaccines, Lancet 360;1243-1245, 2002.
21. Hombach J: Vaccines against dengue: a review of current candidate vaccines at advanced development stages, Rev Panam Salud Publica 21;254-260, 2007.
22. Guy B, Almond JW: Towards a dengue vaccine: progress to date and remaining challenges, Comp Immunol Microbiol Infect Dis 31;289-252, 2008.
23. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W: Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate, J Infect Dis 204;442-450, 2011.
24. Simmons M, Burgess T, Lynch J, Putnak R: Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy, Virology 396;280-288, 2010.
25. Paris RM, Kim JH, Robb ML, Michael NL: Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1, Expert Rev Vaccines 9;1055-1069, 2010.
26. Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgani A, Colloca S, Cortese R, Gilbert SC, Draper SJ: Prime-boost vectored malaria vaccines: progress and prospects, Hum Vaccin 6;78-83, 2010.
27. Vázquez-Blomquist D, Quintana D, Duarte CA: Modified vaccinia virus-Ankara (MVA) priming and fowlpox-virus booster elicit a stronger CD8+ T cell response in mice against an HIV-1 epitope than does a DNA/poxvirus prime-booster approach, Biotechnol Appl Biochem 39;
313-318, 2004.
28. Lu J, Wang C, Zhou Z, Zhang Y, Gao T, Shi C, Chen Z, Chen L, Cai C, Fan X: Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein, Clin Dev Immunol 2011;617892, 2011.
29. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sindon R, Smith GL, Hill AV: Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara, Nat Med 4: 397-402, 1998.
30. Rollier C, Viercaux FJ, Paranhos-Baccala G, Drexhage JA, Verstrepen BE, Berland JH, Hermod N, Barnfield C, Lijestrom P, Lasarte JJ, Ruiz J, Inchauspe G, Heeney JL: Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting, J Infect Dis 192:920-929, 2005.
31. Wu L, Kong WP, Nabel GJ: Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens, J Virol 79:8024-8031, 2005.
32. Barouch DH, Nabel GJ: Adenovirus vector-based vaccines for human immunodeficiency virus type 1, Hum Gene Ther 16:149-156, 2005.
33. Tittel M, Stoddard AM, Flynn BJ, Darrah PA, Wu CY, Wille U, Shah JA, Huang Y, Xu L, Betts MR, Nabel GJ, Seder RA: Prime-boost vaccination with HIV-1 Gag protein and cytotoxic phosphatase guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses, J Immunol 171:2538-2547, 2003.
34. Men R, Wyatt L, Tokimatsu I, Anakali S, Shameem G, Ellkins R, Chanock R, Moss B, Lai CJ: Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge, Vaccine 18:3113-3122, 2000.
35. Eo SK, Lee S, Chun S, Rouse BT: Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines, J Virol 75: 569-578, 2001.
36. Walthou AF, Temple GF, Brasch MA, Huntley JL, Lonson MA, van den Heuvel S, Vidal M: GATEWAY recombinatorial cloning' application to the cloning of large numbers of open reading frames or ORFomes, Methods Enzymol 328: 575-592, 2000.
37. Chakrabarti S, Berchling K, Moss B: Vaccinia virus expression vector: ccppression of beta-galactosidase provides visual screening of recombinant virus plaques, Mol Cell Biol 5:3403-3409, 1985.
38. Graziani-Bowering GM, Graham JM, Filion LG: A quick, easy and inexpensive method for the isolation of human peripheral blood monocytes, J Immunol Methods 207: 157-168, 1997.
39. Frensch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, Scheffold A, Thiel A: Direct access to CD4+ T cells specific for defined antigens according to CD154 expression, Nat Med 11:1118-1124, 2005.
40. Chattopadhyay PK, Yu J, Roederer M: A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles, Nat Med 11:1113-1117, 2005.
41. Aleyas AG, Han YW, George JA, Kim B, Kim K, Lee CK, Eo SC: Multifront assault on antigen presentation by Japanese encephalitis virus subverts CD8+ T cell responses, J Immunol 185:1439-1441, 2010.
42. Ladhache SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC, November FJ, Villingier F, Amara RR, Kahn M, Hu SL, Li S, Li Z, Frankel FR, Robert-Guroff M, Johnson WE, Lieberman J, Ruprecht RM: Prime-boost vaccination with heterologous live vectors encoding SIV gag and multinic HIV-1 gp160 protein: efficacy against repeated mucosal RS clade C SHIV challenges, Vaccine 29:5611-5622, 2011.
43. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lai CY, Graham BS, Nabel GJ, McElrath MJ: National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network: HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable, J Immunol 187:3931-3941, 2001.
44. Kim SJ, Kim HK, Han YW, Aleyas AG, George JA, Yoon HA, Yoo DJ, Kim K, Eo SK: Multiple alternating immunizations with DNA vaccine and replication incompetent adenovirus expressing gB of pseudorabies virus protect animals against lethal virus challenge, J Microbiol Biotechnol 18:1326-1334, 2008.
45. DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A: Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectorized vaccine candidate against Ebola virus elicits a neutralizing antibody response, Vaccine 29:17-25, 2010.
46. Pan Z, Zhang X, Geng S, Fang Q, You M, Zhang L, Jiao X, Liu X: Prime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhi-murium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus, Clin Vaccine Immunol 17:518-523, 2010.
47. Ding H, Tsai C, Gutiérrez RA, Zhou F, Buchy P, Deubel V, Zhou P: Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus, PLoS One 6e16563, 2011.
48. Eo SK, Gierynska M, Kumar AA, Rouse BT: Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules, J Immunol 166:5473-5479, 2001.
49. Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Sait LJ: High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen, Clin Vaccine Immunol 13:475-485, 2006.
50. Neeson P, Boyer J, Kumar S, Lewis MG, Mattias L, Veazey IMVUNELINE http://www.ksimm.or.kr Volume 11 Number 5 October 2011

R, Weiner D, Paterson Y: A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenotype. Virology 354;299-315, 2006.

51. Sandau MM, Kohlmeier JE, Woodland DL, Jameson SC: IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool. J Immunol 184;35-44, 2010.